# Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy

Study · id `cardio:ct-nct03262363` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03262363](<https://clinicaltrials.gov/study/NCT03262363>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03262363

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.

## Technical summary

Registry record NCT03262363. Randomized; triple masking; primary purpose treatment. Start 2018-08-01 (anticipated); primary completion 2019-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 176 participants (planned count; ClinicalTrials.gov record NCT03262363, source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)
- Planned start: 2018-08-01 (anticipated) (ClinicalTrials.gov record NCT03262363, source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)
- Primary completion: 2019-02-28 (anticipated) (ClinicalTrials.gov record NCT03262363, source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)
- Completion: 2019-04-30 (anticipated) (ClinicalTrials.gov record NCT03262363, source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT03262363, source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03262363-2018-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
- Acronym: CURCUNRF2
- Condition: Chronic Kidney Diseases
- Condition: Diabetes Mellitus, Type 2
- Condition: Polymorphism
- Intervention (Combination product): Curcumin/NFE2L2 A&gt;G
- Intervention (Combination product): Placebo/NFE2L2 A&gt;G
- Lead sponsor: Unidad de Investigacion Medica en Enfermedades Renales
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 06972236deea088c84e9b8b4163312f49e3417946573440d9fb9650e76cef934
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
